Figure 3.
Change in daily step counts*. *Change from baseline in average daily step count measured by actigraphy at baseline, day 56 and day 90 for placebo and GSK2881078 treatment groups for (A) females and (B) males. Participants wore an accelerometer for 7 days continuously; data were analysed for participants with a minimum of 8-hour daily wear time for at least 4 days. Note: the number of participants at baseline, day 56 and day 90 were: GSK2881078 1 mg: 20, 14 and 17; female placebo: 20, 17 and 17; GSK2881078 2 mg: 21, 17 and 14; and male placebo: 20, 14 and 14. Error bars indicate ±SD from the mean.